reports
- Guy Sips
- Jacob Mekhael
- Kristof Samoy
- Livio Luyten
- Lynn Hautekeete
- Michiel Declercq
- Thibault Leneeuw
- Thomas Couvreur
- Thomas Vranken
- Wim Hoste
- Wim Lewi
Dynamic Top Pick List Update June: Removing Merus, Shurgard and Adyen ...
In this June update, we've made four adjustments to the KBC Securities Dynamic Top Pick List: 1.Merus (Removed – 27 May) was removed following the release of strong interim Phase 2 data at the ASCO 2025 conference. Its lead asset, petosemtamab, in combination with Keytruda, showed a 63% overall response rate in first-line treatment of head and neck cancer—significantly outperforming Keytruda monotherapy. The resulting share price surge validated our investment thesis. 2. Adyen (Removed) has de...
FAGR FAGRON SA
EVS EVS BROADCAST EQUIPMENT SA
XIOR XIOR STUDENT HOUSING N.V.
DIE D'IETEREN SA
SOF SOFINA SA
ROYAL VOPAK NV
MELE MELEXIS NV
KIN KINEPOLIS GROUP NV
MRUS MERUS B V
ADYEN ADYEN NV
WDP WAREHOUSES DE PAUW SCA
AZE AZELIS GROUP NV
DEME DEME GROUP NV
SHUR SHURGARD SELF STORAGE LIMITED
- ING Helpdesk
- Jacob Mekhael
Zealand Pharma FIRST LOOK: Submits glepaglutide MAA to the EMA in shor...
Zealand announced the submission of a marketing authorization application (MAA) to the European Medicines Agency (EMA) for glepaglutide twice weekly (long-acting GLP-2 analog) in adults with short bowel syndrome (SBS). Looking ahead, we look forward to the initiation of the confirmatory phase 3 trial in the US, expected in 2H25. Beyond glepaglutide, which represents a small fraction of our SOTP, additional phase 1b data (higher dosing and longer treatment) for dapiglutide (long acting GLP-1/GLP-...
- Hilde Van Boxstael
- Jacob Mekhael
- Kristof Samoy
- Wim Lewi
Zealand Pharma submits Marketing Authorization Application to the Euro...
Zealand Pharma submits Marketing Authorization Application to the European Medicines Agency for glepaglutide in short bowel syndrome Press release – No. 10 / 2025 Zealand Pharma submits Marketing Authorization Application to the European Medicines Agency for glepaglutide in short bowel syndrome Copenhagen, Denmark, June 2, 2025 – Zealand Pharma A/S (Nasdaq: ZEAL) (“Zealand”) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced the submission of a Marketing Authorization Application (MAA) to the European...
AVTL successfully completed IPO
AVTL successfully completed IPO AVTL successfully completed IPORotterdam, the Netherlands, 02 June 2025 Today, we announce an update regarding the primary equity issue of our joint venture AVTL.AVTL has successfully completed its IPO. The issue price for the IPO was INR 235 per share which is at the top end of the previously announced price band. The size of the primary equity issue is INR 2,800 crore (approximately EUR 290 million). The board of AVTL issued an equivalent of 10.75% of new equity shares. As a result of the issuance of new shares, Vopak’s shareholding reduced from 47.31% to 4...
- ING Helpdesk
Transactions in Zealand Pharma shares and/or related securities by per...
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Company announcement – No. 13 / 2025 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhagen, Denmark, May 27, 2025 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, has received infor...
- Charlotte Vaisse
- Fehmi Ben Naamane
- Oddo Sustainability Team
ELIOR ELIOR GROUP SA
CLN CLARIANT AG
WTB WHITBREAD PLC
ZVTG ZAVAROVALNICA TRIGLAV D.D.
GLJ GRENKE AG
RBT ROBERTET SA
POS PORR AG
CAI CA IMMOBILIEN ANLAGEN AG
WIE WIENERBERGER AG
ROYAL VOPAK NV
SBO SCHOELLER-BLECKMANN OILFIELD EQUIPMENT AG
SHOT SCANDIC HOTELS GROUP
HBH HORNBACH HOLDING AG & CO. KGAA
FNTN FREENET AG
MEL MELIA HOTELS INTERNATIONAL S.A.
NHH NH HOTEL GROUP SA
2CRSI 2CRSI SA
GRE GRENERGY RENOVABLES
IHG INTERCONTINENTAL HOTELS GROUP PLC
MFEA MEDIASET NV
DSPW DOOSAN SKODA POWER A.S.
LOUP SOCIETE L.D.C.
- Charlotte Vaisse
- Fehmi Ben Naamane
- Oddo Sustainability Team
ELIOR ELIOR GROUP SA
CLN CLARIANT AG
WTB WHITBREAD PLC
ZVTG ZAVAROVALNICA TRIGLAV D.D.
GLJ GRENKE AG
RBT ROBERTET SA
POS PORR AG
CAI CA IMMOBILIEN ANLAGEN AG
WIE WIENERBERGER AG
ROYAL VOPAK NV
SBO SCHOELLER-BLECKMANN OILFIELD EQUIPMENT AG
SHOT SCANDIC HOTELS GROUP
HBH HORNBACH HOLDING AG & CO. KGAA
FNTN FREENET AG
MEL MELIA HOTELS INTERNATIONAL S.A.
NHH NH HOTEL GROUP SA
2CRSI 2CRSI SA
GRE GRENERGY RENOVABLES
IHG INTERCONTINENTAL HOTELS GROUP PLC
MFEA MEDIASET NV
DSPW DOOSAN SKODA POWER A.S.
LOUP SOCIETE L.D.C.
- ING Helpdesk
Benelux Morning Notes
Ackermans & van Haaren: Solid 1Q25. Ascencio: Resilient results. Gimv: NAV a tad higher than expected, underlying companies surprisingly strong. IBA: Soft start in Technologies, 2025 and 2028 guidance reiterated. OCI: In-line 1Q25 trading update. Vopak: IPO of AVTL - value coming to the surface
- Kristof Samoy
Vopak Indian JV on the brink of IPO debut
This morning during trading, Vopak issued a press release commenting on the IPO process of its Indian joint venture AVTL. The final prospectus was filed and the upper end of the price band is roughly in line with the attractive pricing of the private placement occurring last October. We applaud the important hurdle being taken. Upon completion of the IPO, expected sizeable cash proceeds (€288m – upper end of range – 100% JV) will fund AVTL's growth and free up cash at Vopak holding. The latter c...
AVTL files Red Herring Prospectus
AVTL files Red Herring Prospectus AVTL files Red Herring Prospectus Rotterdam, the Netherlands, 21 May 2025Today, we announce an update regarding the primary equity issue of our joint venture AVTL.AVTL has received approval from the Securities and Exchange Board of India (‘SEBI’) and has filed the Red Herring Prospectus with the Registrar of Companies Gujarat at Ahmedabad and thereafter submitted to SEBI and the stock exchanges. The price band for the primary equity issue was approved by the board of AVTL on 20 May 2025, which ranges between INR 223 to INR 235 per share. The total IPO size...
- Guy Sips
- Jacob Mekhael
- Kristof Samoy
- Thomas Couvreur
- Thomas Vranken
- Wim Hoste
Zealand Pharma continues to strengthen strategic leadership of innovat...
Zealand Pharma continues to strengthen strategic leadership of innovation in obesity and related conditions with appointment of Steven Johnson as Chief Development Officer Press release – No. 9 / 2025 Zealand Pharma continues to strengthen strategic leadership of innovation in obesity and related conditions with appointment of Steven Johnson as Chief Development Officer Steven will lead the regulatory and development strategies that position Zealand Pharma at the forefront of innovation in the management of obesity and other related complications He joins CMO David Kendall and recently...
Zealand Pharma to participate in upcoming healthcare investor conferen...
Zealand Pharma to participate in upcoming healthcare investor conferences in May and June 2025 Press release – No. 8 / 2025 Zealand Pharma to participate in upcoming healthcare investor conferences in May and June 2025 Copenhagen, Denmark, May 12, 2025 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced that the company will participate in the following healthcare investor conferences in May and June 2025: Bank of America Global Healthcare Conference, May 13-15 in L...
Zealand Pharma announces closing of collaboration and license agreemen...
Zealand Pharma announces closing of collaboration and license agreement with Roche Company announcement – No. 12 / 2025 Zealand Pharma announces closing of collaboration and license agreement with Roche Copenhagen, Denmark, May 9, 2025 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announces that all closing conditions in the collaboration and license agreement with Roche have been satisfied, including regulatory conditions, and the ag...
- Hilde Van Boxstael
- Jacob Mekhael
- Michiel Declercq
- Thomas Vranken
- Wim Hoste
- Wim Lewi
- Jacob Mekhael
Zealand Pharma Uneventful 1Q25 results, dapi phase 1 higher dose data ...
Zealand reported uneventful 1Q25 results with a cash position of DKK 8,545m to be supplemented with a $1.4b (approx. DKK 9.24b) upfront from Roche in 2Q25. Pipeline timelines were reiterated, and while the later stage datasets are expected in 1H26, we look forward to results from the higher dose cohort from the phase 1b trial of dapiglutide (GLP-1/GLP-2 analog) in overweight/obese patients in 2Q25. In addition, we expect read-through from cagrisema's (GLP-1/amylin analog) full dataset potentiall...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.